Janine Stutterheim

788 total citations
23 papers, 379 citations indexed

About

Janine Stutterheim is a scholar working on Cancer Research, Neurology and Molecular Biology. According to data from OpenAlex, Janine Stutterheim has authored 23 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cancer Research, 13 papers in Neurology and 10 papers in Molecular Biology. Recurrent topics in Janine Stutterheim's work include Neuroblastoma Research and Treatments (13 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Acute Myeloid Leukemia Research (4 papers). Janine Stutterheim is often cited by papers focused on Neuroblastoma Research and Treatments (13 papers), Cancer, Hypoxia, and Metabolism (10 papers) and Acute Myeloid Leukemia Research (4 papers). Janine Stutterheim collaborates with scholars based in Netherlands, Germany and Australia. Janine Stutterheim's co-authors include Godelieve A.M. Tytgat, C. Ellen van der Schoot, Lily Zappeij‐Kannegieter, Rogier Versteeg, Huib N. Caron, Max M. van Noesel, Frank Berthold, Rob Dee, Lieke M. J. van Zogchel and H.N. Caron and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Janine Stutterheim

22 papers receiving 378 citations

Peers

Countries citing papers authored by Janine Stutterheim

Since Specialization

Citations

This map shows the geographic impact of Janine Stutterheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janine Stutterheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janine Stutterheim more than expected).

Fields of papers citing papers by Janine Stutterheim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janine Stutterheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janine Stutterheim. The network helps show where Janine Stutterheim may publish in the future.

Co-authorship network of co-authors of Janine Stutterheim

This figure shows the co-authorship network connecting the top 25 collaborators of Janine Stutterheim. A scholar is included among the top collaborators of Janine Stutterheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janine Stutterheim. Janine Stutterheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges 2025 ·Haematologica ·Janine Stutterheim, Inge M. van der Sluis, (unknown), Rob Pieters, Ronald W. Stam	1
2	APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias 2024 ·Blood ·Elisabeth Salzer, Janine Stutterheim, Branko Cuglievan, Blake Tomkinson, Mollie Leoni, Harm van Tinteren, Alwin D. R. Huitema, Marieke Willemse, Gwen Nichols, Francisco Bautista, Sarah K. Tasian, Todd M. Cooper, C. Michel Zwaan	1
3	KMT2A-rearranged acute lymphoblastic leukaemia 2024 ·SHILAP Revista de lepidopterología ·Rishi S. Kotecha, Rob Pieters, Janine Stutterheim	3
4	Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? 2024 ·Leukemia ·Janine Stutterheim, (unknown), Hester A. de Groot‐Kruseman, Edwin Sonneveld, Válerie de Haas, (unknown), C. Ellen van der Schoot, Vincent H. J. van der Velden, Rob Pieters	2
5	Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study 2024 ·Journal of Experimental & Clinical Cancer Research ·Lieke M. J. van Zogchel, Boris Decarolis, (unknown), Lily Zappeij‐Kannegieter, (unknown), (unknown), Thorsten Simon, Frank Berthold, Max M. van Noesel, Marta Fiocco, C. Ellen van der Schoot, Barbara Hero, Janine Stutterheim, (unknown)	1
6	Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia 2024 ·International Journal of Molecular Sciences ·(unknown), Pauline Schneider, Susan T.C.J.M. Arentsen-Peters, (unknown), Janine Stutterheim, Rob Pieters, C. Michel Zwaan, Ronald W. Stam	8
7	Cell-Free RNA from Plasma in Patients with Neuroblastoma: Exploring the Technical and Clinical Potential 2023 ·Cancers ·(unknown), (unknown), Lieke M. J. van Zogchel, (unknown), (unknown), Lily Zappeij‐Kannegieter, Laura Bongiovanni, (unknown), Janine Stutterheim, C. Ellen van der Schoot, Alain de Bruin, Godelieve A.M. Tytgat	5
8	Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors 2023 ·Frontiers in Oncology ·Lieke M. J. van Zogchel, (unknown), (unknown), (unknown), Ellen Stelloo, Joost F. Swennenhuis, Harma Feitsma, Max van Min, Erik Splinter, Margit Bleijs, Marian J.A. Groot Koerkamp, Willemijn B. Breunis, Michael T. Meister, (unknown), Frank C. P. Holstege, Jan J. Molenaar, Wendy W.J. de Leng, Janine Stutterheim, C. Ellen van der Schoot, Godelieve A.M. Tytgat	2
9	Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease 2021 ·Clinical Cancer Research ·(unknown), (unknown), Lily Zappeij‐Kannegieter, Lieke M. J. van Zogchel, Marta Fiocco, Max M. van Noesel, Johannes H. M. Merks, C. Ellen van der Schoot, Godelieve A.M. Tytgat, Janine Stutterheim	11
10	Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors 2021 ·JCO Precision Oncology ·Lieke M. J. van Zogchel, (unknown), O. J. H. M. Verhagen, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Johannes H. M. Merks, Marry van den Heuvel‐Eibrink, Antoinette Y. N. Schouten‐van Meeteren, Janine Stutterheim, C. Ellen van der Schoot, Godelieve A.M. Tytgat	21
11	Abstract A53: Hypermethylated RASSF1A as circulating tumor marker in pediatric and adolescent solid tumors 2020 ·Clinical Cancer Research ·Lieke M. J. van Zogchel, João Lobo, (unknown), (unknown), (unknown), Janine Stutterheim, Lily Zappeij‐Kannegieter, Leendert H. J. Looijenga, C. Ellen van der Schoot, Godelieve A.M. Tytgat	0
12	Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma 2020 ·JCO Precision Oncology ·Lieke M. J. van Zogchel, (unknown), (unknown), Janine Stutterheim, (unknown), Lily Zappeij‐Kannegieter, (unknown), (unknown), (unknown), C. Ellen van der Schoot, Godelieve A.M. Tytgat	17
13	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients 2016 ·European Journal of Cancer ·(unknown), Boris Decarolis, Janine Stutterheim, Lily Zappeij‐Kannegieter, Frank Berthold, (unknown), Thorsten Simon, Marta Fiocco, Max M. van Noesel, Huib N. Caron, C. Ellen van der Schoot, Barbara Hero, Godelieve A.M. Tytgat	10
14	Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma 2015 ·Pediatric Blood & Cancer ·(unknown), Janine Stutterheim, (unknown), Lily Zappeij‐Kannegieter, Boris Decarolis, Barbara Hero, Frank Berthold, (unknown), Thorsten Simon, Marta Fiocco, Carlijn Voermans, Max M. van Noesel, Huib N. Caron, C. Ellen van der Schoot, Godelieve A.M. Tytgat, (unknown)	21
15	Stability of PCR Targets for Monitoring Minimal Residual Disease in Neuroblastoma 2012 ·Journal of Molecular Diagnostics ·Janine Stutterheim, Lily Zappeij‐Kannegieter, Ingrid Øra, (unknown), Johannes Bras, (unknown), Rogier Versteeg, Huib N. Caron, C. Ellen van der Schoot, Godelieve A.M. Tytgat	17
16	Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma 2011 ·Clinical Cancer Research ·Janine Stutterheim, (unknown), (unknown), Rogier Versteeg, Huib N. Caron, Godelieve A.M. Tytgat, C. Ellen van der Schoot	28
17	The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma 2011 ·European Journal of Cancer ·Janine Stutterheim, Lily Zappeij‐Kannegieter, Rogier Versteeg, H.N. Caron, C. Ellen van der Schoot, Godelieve A.M. Tytgat	43
18	Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers 2009 ·Clinical Chemistry ·Janine Stutterheim, (unknown), Lily Zappeij‐Kannegieter, Bilgehan Yalçın, Rob Dee, Max M. van Noesel, Frank Berthold, Rogier Versteeg, Huib N. Caron, C. Ellen van der Schoot, Godelieve A.M. Tytgat	55
19	HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity 2008 ·Molecular Immunology ·Janine M. van Gils, Janine Stutterheim, (unknown), Jaap Jan Zwaginga, Leendert Porcelijn, Masja de Haas, Peter L. Hordijk	31
20	Quantitative Evaluation of Circulatory Left-to-right Shunts by Ascorbate Dilution Using a Single Venous Catheter for Injection and Measurement 1969 ·Cardiovascular Research ·B. Oeseburg, Esther Meijer, Janine Stutterheim, W. G. Zijlstra	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact